Ep. 255, Chapter 3: Biotech Investors' Pet Peeves with Yaniv Sneor

24:42 – 36:33

Sneor criticizes "spray and pray" pitches that lack personalization and don't align with the group's specific investment criteria, as well as "scientific pitches" that resemble a poster presentation, rather than a compelling financial story focused on the exit strategy and potential returns. He also cautions that familial relationships can compromise business accountability. Mid Atlantic Bio Angels offers guidance and network access, and they are drawn to opportunities with orphan drug designations that offer potential for expanded indications, or areas so attractive to larger pharma/device companies that early acquisition is likely, providing an efficient path to exit for investors.